NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth

Accelerating U.S. heart, liver & lung transplants plus strong flight data signal major growth ahead.

TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth
Credit: PRNewswire/TransMedics
Already have an account? Sign in.
07/01/2026 · 3:38 PM
TMDX
/ Don’t stop at just one post.

Related↓

Why TransMedics Stock Fell — and Why Analysts Aren’t Worried
01/21/2026 · 3:34 PM

Why TransMedics Stock Fell — and Why Analysts Aren’t Worried

TransMedics shares dropped after FDA clearance of a rival liver perfusion system, but TD Cowen says the selloff is overdone and sees no real competitive threat.

/ Subscriber only
/ Read more

Feed↓

BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough
07/21/2026 · 1:18 PM

BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough

BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.

/ Subscriber only
TSMC Announces Up to 10% Price Hike for Advanced Chips Starting 2027
Featured/ 07/21/2026 · 12:54 PM

TSMC Announces Up to 10% Price Hike for Advanced Chips Starting 2027

Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.

/ Subscriber only
Genuine Parts Cuts Profit Forecast, Denies Takeover Rumors as Rivals Rise
07/21/2026 · 12:19 PM

Genuine Parts Cuts Profit Forecast, Denies Takeover Rumors as Rivals Rise

Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe